Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Abstract Background/objective Osteoporosis is a global health concern with an increasing prevalence worldwide. Denosumab is an antiresoptive agent that has been demonstrated to be effective and safe in osteoporotic patients. This study aimed to compare the efficacy and safety of the biosimilar denos...

Full description

Bibliographic Details
Main Authors: Ahmadreza Jamshidi, Mahdi Vojdanian, Mohsen Soroush, Mahmoud Akbarian, Mehrdad Aghaei, Asghar Hajiabbasi, Zahra Mirfeizi, Alireza Khabbazi, Gholamhosein Alishiri, Anousheh Haghighi, Ahmad Salimzadeh, Hadi Karimzadeh, Fatemeh Shirani, Mohammad Reza Hatef Fard, MohammadAli Nazarinia, Soosan Soroosh, Nassim Anjidani, Farhad Gharibdoost
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Arthritis Research & Therapy
Subjects:
Denosumab
Arylia
Prolia®
Osteoporosis
Biosimilar
Online Access:https://doi.org/10.1186/s13075-022-02840-8

Internet

https://doi.org/10.1186/s13075-022-02840-8

Similar Items